Home
LigaChemBio Sciences

三月 2026的LigaChemBio Sciences市场份额分析

리가켐 바이오사이언스는 신약개발에 30년 이상 헌신하며 혁신적인 기술과 Open Innovation을 통해 글로벌 신약개발의 새로운 길을 개척하고 있습니다.

行业: 不适用

域ligachembio.com

成立年份--

员工51 - 200

年营收--

LigaChemBio Sciences

LigaChemBio Sciences（包含公司地区分支机构）

ligachembio.com

查看更多网站流量和参与度信息

LigaChemBio Sciences热门域名的总访问量

了解LigaChemBio Sciences市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

ligachembio.com10.4K

使用销售情报查看更多信息

LigaChemBio Sciences热门域名的平均访问时长

分析LigaChemBio Sciences参与度指标。

过去 3 个月的平均访问时长

子公司明细

ligachembio.com00:00:54

使用销售情报查看更多信息

LigaChemBio Sciences热门域名的平均页面浏览量

了解LigaChemBio Sciences如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

ligachembio.com1.73

使用销售情报查看更多信息

LigaChemBio Sciences 排名靠前的竞争对手（按域名）

三月 2026的热门相似网站，按亲和力排名

arvinas.com公司名称Arvinas员工201 - 500总部美国, 康涅狄格州, New Haven年营收$200M - $500M总访问量20.1K健康 > 生物科技及制药

LigaChemBio Sciences 采用的主要技术

这些是排名前 LigaChemBio Sciences 的顶级域名所使用的网站技术（按行业分列）

移动设备 (3)

Meta Viewport

小部件 (2)

reCAPTCHA

转化和分析 (1)

Google Analytics

营销 (1)

Google Marketing Platform

更多技术

2

查看全部

LigaChemBio Sciences 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Samsung partnered with LIGACHEM BIOSCIENCES Inc. on Dec 15th '24.Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics' new dedicated ADC facility.

新闻LIGACHEM BIOSCIENCES Inc. invests into Iksuda Therapeutics Limited $25M in investment.Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the right to buy shares from other current major shareholders to eventually take control of the UK-based ADC specialist.

新闻Wuxixdc partners with LIGACHEM BIOSCIENCES Inc..China-based WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced the signing of an expanded Memorandum of Understanding (MoU) with South Korea-based LigaChem Biosciences, Inc., a leader in the development of innovative ADC therapies targeting cancer and other serious diseases.